Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLittle, T.en
dc.contributor.authorPilichiewicz, A.en
dc.contributor.authorRusso, A.en
dc.contributor.authorPhillips, L.en
dc.contributor.authorJones, K.en
dc.contributor.authorNauck, M.en
dc.contributor.authorWishart, J.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorFeinle-Bisset, C.en
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2006; 91(5):1916-1923en
dc.descriptionCopyright © 2006 by The Endocrine Societyen
dc.description.abstractContext: The inhibitory action of glucagon-like peptide-1 (GLP-1) on gastric emptying (GE) is likely to be important in mediating its effects on postprandial glycemia, appetite, and gastrointestinal symptoms. Objective: The objective of the study was to evaluate the effects of "low" and "high" doses of iv GLP-1 on GE, intragastric meal distribution, glycemia, insulinemia, and appetite. Design: Ten healthy males were studied on 3 d. GE of a solid (ground beef)/liquid (glucose) meal, blood glucose, plasma insulin, glucagon and glucose-dependent insulinotropic peptide, appetite perceptions, and gastrointestinal symptoms were evaluated during iv infusion of: 1) GLP-1 at 0.3 pmol·kg–1·min–1 (GLP-1 0.3); 2) GLP-1 at 0.9 pmol·kg–1·min–1 (GLP-1 0.9); and 3) 0.9% saline. Results: GLP-1 0.3 and 0.9 slowed GE of solid (intragastric retention at t = 100 min; saline: 28 ± 5%; GLP-1 0.3: 53 ± 6%; GLP-1 0.9: 58 ± 7%; P < 0.001) and liquid (time for 50% of the liquid to empty, saline: 28 ± 2 min; GLP-1 0.3: 42 ± 7 min; GLP-1 0.9: 50 ± 9 min; P < 0.001). Both doses of GLP-1 induced gastroparesis in about half the cohort and increased meal retention in the distal stomach (P < 0.05). GLP-1 attenuated the rises in glucose, insulin, and glucose-dependent insulinotropic peptide (P < 0.05). There was an inverse relationship between blood glucose at t = 15 min and the time for 50% of the liquid to empty (r = –0.70, P < 0.001). Conclusions: In healthy subjects exogenous GLP-1 increases meal retention in the distal stomach and, even when administered in a "low" dose, frequently induces "gastroparesis," and the effects of GLP-1 on postprandial glycemia are predictable on the basis of its effect on GE, supporting the concept that GE is a major target mechanism for the clinical use of incretin mimetics.en
dc.description.statementofresponsibilityTanya J. Little, Amelia N. Pilichiewicz, Antonietta Russo, Liza Phillips, Karen L. Jones, Michael A. Nauck, Judith Wishart, Michael Horowitz and Christine Feinle-Bisseten
dc.publisherEndocrine Societyen
dc.subjectStomach; Humans; Gastric Inhibitory Polypeptide; Glucagon; Insulin; Blood Glucose; Treatment Outcome; Injections, Intravenous; Hunger; Appetite; Satiety Response; Gastric Emptying; Postprandial Period; Adult; Male; Glucagon-Like Peptide 1en
dc.titleEffects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responsesen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidLittle, T. [0000-0001-9814-1036]en
dc.identifier.orcidPhillips, L. [0000-0002-9066-717X]en
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidFeinle-Bisset, C. [0000-0001-6848-0125]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.